8-K filed April 29, 2026, 7:59 PM ET ticker BBOT CIK 0001869105

leadership confidence high sentiment neutral materiality 0.40

BridgeBio Oncology enters consulting agreement with former CEO Eli Wallace; equity vesting continues for 12 months

BridgeBio Oncology Therapeutics, Inc.

Dr. Wallace provides R&D advisory services for 12 months retroactive to April 21, 2026.
Compensation: continued vesting of outstanding equity awards subject to service through each vesting date.
Vested stock options exercisable up to 2 years after consulting termination or original expiry, whichever earlier.
Wallace also receives Tier 1 severance benefits under the Executive Severance Plan via Separation Agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Pedro J. Beltran

Member of the Board of Directors

BBOT · BridgeBio Oncology Therapeutics, Inc.

Effective: 2026-04-20
Filed: April 29, 2026, 7:59 PM ET

Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.

Departed

Eli Wallace

President and Chief Executive Officer

BBOT · BridgeBio Oncology Therapeutics, Inc.

Effective: 2026-04-20
Successor: Pedro J. Beltran
Filed: April 29, 2026, 7:59 PM ET

Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.

Appointed

Pedro J. Beltran

President and Chief Executive Officer

BBOT · BridgeBio Oncology Therapeutics, Inc.

Effective: 2026-04-20
Filed: April 29, 2026, 7:59 PM ET

Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.

Departed

Eli Wallace

Member of the Board of Directors

BBOT · BridgeBio Oncology Therapeutics, Inc.

Effective: 2026-04-20
Successor: Pedro J. Beltran
Filed: April 29, 2026, 7:59 PM ET

Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Pedro J. Beltran was appointed as Member of the Board of Directors at BridgeBio Oncology Therapeutics, Inc..

Action: appointed
Role: Member of the Board of Directors

Exact text from the filing

Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eli Wallace resigned as President and Chief Executive Officer at BridgeBio Oncology Therapeutics, Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Pedro J. Beltran was appointed as President and Chief Executive Officer at BridgeBio Oncology Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eli Wallace resigned as Member of the Board of Directors at BridgeBio Oncology Therapeutics, Inc..

Action: resigned
Role: Member of the Board of Directors

Exact text from the filing

Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.

View on SEC.gov

BridgeBio Oncology Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-191512

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.